Chordate Medical Holding AB (publ) (CMH.ST)
SEK 12.6
(-1.18%)
SEK 12.6
(-1.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.3 Million SEK | 10.06% |
| 2022 | 28.05 Million SEK | 18.56% |
| 2021 | 23.66 Million SEK | 7.89% |
| 2020 | 21.93 Million SEK | -17.58% |
| 2019 | 26.61 Million SEK | 0.09% |
| 2018 | 26.58 Million SEK | 12.41% |
| 2017 | 23.65 Million SEK | 29.43% |
| 2016 | 18.27 Million SEK | 7.77% |
| 2015 | 16.95 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.61 Million SEK | -35.91% |
| 2024 Q2 | 8.2 Million SEK | 24.11% |
| 2023 Q4 | 10.31 Million SEK | 83.86% |
| 2023 Q1 | 7.2 Million SEK | -14.88% |
| 2023 Q3 | 5.6 Million SEK | -27.65% |
| 2023 Q2 | 7.75 Million SEK | 7.61% |
| 2023 FY | 30.88 Million SEK | 10.06% |
| 2022 Q1 | 7.4 Million SEK | -1.68% |
| 2022 FY | 28.05 Million SEK | 18.56% |
| 2022 Q4 | 8.46 Million SEK | 37.07% |
| 2022 Q3 | 6.17 Million SEK | 2.62% |
| 2022 Q2 | 6.01 Million SEK | -18.72% |
| 2021 FY | 23.66 Million SEK | 7.89% |
| 2021 Q1 | 6.07 Million SEK | 0.47% |
| 2021 Q2 | 5.9 Million SEK | -2.82% |
| 2021 Q3 | 4.16 Million SEK | -29.42% |
| 2021 Q4 | 7.52 Million SEK | 80.79% |
| 2020 Q1 | 6.25 Million SEK | -19.74% |
| 2020 Q4 | 6.04 Million SEK | 32.41% |
| 2020 FY | 21.93 Million SEK | -17.58% |
| 2020 Q3 | 4.56 Million SEK | -9.94% |
| 2020 Q2 | 5.06 Million SEK | -19.03% |
| 2019 FY | 26.61 Million SEK | 0.09% |
| 2019 Q1 | 6.13 Million SEK | -2.68% |
| 2019 Q2 | 6.15 Million SEK | 0.21% |
| 2019 Q3 | 6.52 Million SEK | 6.03% |
| 2019 Q4 | 7.79 Million SEK | 19.55% |
| 2018 Q3 | 6.63 Million SEK | -0.31% |
| 2018 FY | 26.58 Million SEK | 12.41% |
| 2018 Q2 | 6.65 Million SEK | -0.8% |
| 2018 Q1 | 6.71 Million SEK | -9.72% |
| 2018 Q4 | 6.3 Million SEK | -4.93% |
| 2017 Q1 | 4.94 Million SEK | -8.17% |
| 2017 FY | 23.65 Million SEK | 29.43% |
| 2017 Q2 | 5.69 Million SEK | 15.18% |
| 2017 Q3 | 5.59 Million SEK | -1.75% |
| 2017 Q4 | 7.43 Million SEK | 32.95% |
| 2016 Q3 | 4.12 Million SEK | -13.29% |
| 2016 Q2 | 4.75 Million SEK | 0.0% |
| 2016 FY | 18.27 Million SEK | 7.77% |
| 2016 Q4 | 5.37 Million SEK | 30.47% |
| 2015 FY | 16.95 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 98.42% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 99.786% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 99.786% |
| Arcoma AB | 53.25 Million SEK | 97.542% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | 73.653% |
| BICO Group AB (publ) | 2.84 Billion SEK | 99.954% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 99.378% |
| CellaVision AB (publ) | 295.99 Million SEK | 99.558% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 98.101% |
| C-Rad AB (publ) | 3.8 Million SEK | 65.548% |
| Duearity AB (publ) | 21.58 Million SEK | 93.935% |
| Dignitana AB (publ) | 74.73 Million SEK | 98.248% |
| Episurf Medical AB (publ) | 2.7 Million SEK | 51.512% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.988% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | 92.818% |
| Iconovo AB (publ) | 63.35 Million SEK | 97.934% |
| Integrum AB (publ) | 90.57 Million SEK | 98.555% |
| Luxbright AB (publ) | 23.09 Million SEK | 94.33% |
| Mentice AB (publ) | 237.06 Million SEK | 99.448% |
| OssDsign AB (publ) | 175.6 Million SEK | 99.254% |
| Paxman AB (publ) | 133.8 Million SEK | 99.022% |
| Promimic AB (publ) | 48.55 Million SEK | 97.304% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 99.194% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 98.129% |
| ScandiDos AB (publ) | 61.03 Million SEK | 97.855% |
| Sectra AB (publ) | 39.06 Million SEK | 96.649% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 99.25% |
| Senzime AB (publ) | 141.51 Million SEK | 99.075% |
| SpectraCure AB (publ) | 12.12 Million SEK | 89.205% |
| Stille AB | 87.21 Million SEK | 98.499% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.976% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 99.703% |